Drug Name: Columvi
Indications: To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy.
Active Ingredient: Glofitamab-gxbm
Company: Genentech, Inc
Approval Date: 6/15/2023
More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf